169 related articles for article (PubMed ID: 26500849)
1. Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia.
Blunt MD; Steele AJ
Leuk Res Rep; 2015; 4(2):60-3. PubMed ID: 26500849
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
[TBL] [Abstract][Full Text] [Related]
3. Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia.
Visentin A; Frezzato F; Severin F; Imbergamo S; Pravato S; Romano Gargarella L; Manni S; Pizzo S; Ruggieri E; Facco M; Brunati AM; Semenzato G; Piazza F; Trentin L
Onco Targets Ther; 2020; 13():9679-9688. PubMed ID: 33061448
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous Inhibition of PI3Kgamma and PI3Kdelta Deteriorates T-cell Function With Implications for Chronic Lymphocytic Leukemia.
Faehling S; Coelho M; Floerchinger A; Schneider C; Stilgenbauer S; Lichter P; Seiffert M; Roessner PM
Hemasphere; 2023 Mar; 7(3):e840. PubMed ID: 36844182
[TBL] [Abstract][Full Text] [Related]
5. The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia.
Brown JR
Semin Oncol; 2016 Apr; 43(2):260-4. PubMed ID: 27040704
[TBL] [Abstract][Full Text] [Related]
6. PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives.
Hus I; Puła B; Robak T
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326722
[TBL] [Abstract][Full Text] [Related]
7. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
Lampson BL; Brown JR
Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
[TBL] [Abstract][Full Text] [Related]
8. Idelalisib.
Zirlik K; Veelken H
Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
[TBL] [Abstract][Full Text] [Related]
9. Oral PI3K-δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib.
Shah A; Barrientos JC
Onco Targets Ther; 2021; 14():2109-2119. PubMed ID: 33790574
[TBL] [Abstract][Full Text] [Related]
10. [Reaserch Advance on Inhibitor Targeting at the B-Cell Receptor Pathway in Chronic Lymphocytic Leukemia --Review].
Ji TT; Chen QN; Tao SD; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):708-712. PubMed ID: 32319422
[TBL] [Abstract][Full Text] [Related]
11. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
[TBL] [Abstract][Full Text] [Related]
12. Expression and function of phosphoinositide 3-kinase delta in mesenchymal stromal cells from normal and leukaemic bone marrow.
Ali AY; Guan Q; Wu X; Hou S; Banerji V; Johnston JB; Wall D; Szwajcer D; Gibson SB; Marshall AJ
Br J Haematol; 2019 Jun; 185(5):883-887. PubMed ID: 30873593
[TBL] [Abstract][Full Text] [Related]
13. Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration.
Ali AY; Wu X; Eissa N; Hou S; Ghia JE; Murooka TT; Banerji V; Johnston JB; Lin F; Gibson SB; Marshall AJ
Leukemia; 2018 Sep; 32(9):1958-1969. PubMed ID: 29479062
[TBL] [Abstract][Full Text] [Related]
14. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
Robak T; Robak P
Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
[TBL] [Abstract][Full Text] [Related]
15. The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment.
Crassini K; Shen Y; O'Dwyer M; O'Neill M; Christopherson R; Mulligan S; Best OG
Br J Haematol; 2018 Sep; 182(5):654-669. PubMed ID: 29978459
[TBL] [Abstract][Full Text] [Related]
16. Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells.
Hock BD; MacPherson SA; McKenzie JL
PLoS One; 2017; 12(3):e0172858. PubMed ID: 28257435
[TBL] [Abstract][Full Text] [Related]
17. PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.
Wang X; Ding J; Meng LH
Acta Pharmacol Sin; 2015 Oct; 36(10):1170-6. PubMed ID: 26364801
[TBL] [Abstract][Full Text] [Related]
18. The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.
Thijssen R; Ter Burg J; van Bochove GG; de Rooij MF; Kuil A; Jansen MH; Kuijpers TW; Baars JW; Virone-Oddos A; Spaargaren M; Egile C; van Oers MH; Eldering E; Kersten MJ; Kater AP
Leukemia; 2016 Feb; 30(2):337-45. PubMed ID: 26338274
[TBL] [Abstract][Full Text] [Related]
19. Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
Greenwell IB; Flowers CR; Blum KA; Cohen JB
Expert Rev Anticancer Ther; 2017 Mar; 17(3):271-279. PubMed ID: 28112970
[TBL] [Abstract][Full Text] [Related]
20. The biology behind PI3K inhibition in chronic lymphocytic leukaemia.
Ortiz-Maldonado V; García-Morillo M; Delgado J
Ther Adv Hematol; 2015 Feb; 6(1):25-36. PubMed ID: 25642313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
